4.2 Article

Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation

Journal

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume 11, Issue 4, Pages 288-296

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.bbmt.2005.01.003

Keywords

nomyeloablative; pulmonary function

Funding

  1. NCI NIH HHS [CA18029, CA15704, K23 CA92058, P01 CA078902, CA78902] Funding Source: Medline
  2. NHLBI NIH HHS [1R01 HL71914-01, HL36444, 1K23HL69860-01] Funding Source: Medline

Ask authors/readers for more resources

Lung function decline is a well-recognized occurrence after myeloablative hematopoietic stem cell transplantation (HCT) that has not been studied after nonmyeloablative conditioning regimens. We examined the lung function of patients before and after 2-Gy total body irradiation-based nonmyelloablative and myeloablative preparative regimens. Before HCT, at day 100, and 1 year after HCT, nonmyeloablative patients had lower 1-second forced expiratory volume (FEV1), forced vital capacity, total lung capacity, residual volume, and carbon monoxide diffiision capacity. However, after transplantation, the risk for experiencing a > 20% per year decrease of FEV1 was significantly lower for nonmyeloablative than myeloablative patients > 50 years of age (odds ratio, 0.3; 95% confidence interval, 0.1-0.8; P = .01). Lower pretransplantation FEV1 was associated with a higher mortality rate for both groups, with the highest mortality risk among patients with a pretransplantation FEV, < 60% (nonmyeloablative: hazard ratio, 3.9; 95% confidence interval, 1.9-8.0; myeloablative: hazard ratio, 7.2; 95% confidence interval, 2.5-21.2). These results suggest that despite having worse lung function, patients who receive the 2-Gy total body irradiation-based nonmyeloablative regimen will likely experience less pulmonary toxicity than patients who receive a myeloablative regimen, and this may have important clinical implications when deciding on a conditioning regimen for patients > 50 years of age with compromised pretransplantation lung function. (c) 2005 American Society for Blood and Marrow Transplantation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available